Damora Therapeutics is trading 5.61% up at $29.57, with no clear company-specific catalyst identified for September 4, 2026.
- The latest release announced inducement grants for three newly hired employees, covering options for 135,400 shares at a $28.18 exercise price; it did not link the announcement to the stock move.
- Broader U.S. markets are lower, so market direction does not clearly explain the gain.